New Hope In Ovarian Cancer Treatment

What’s changing in ovarian cancer treatment - and who has access to it?In this episode, we dive into the biggest innovations transforming ovarian cancer care - from “smart” targeted treatments like PARP inhibitors and antibody-drug conjugates (ADCs), to advances in surgery, immunotherapy, and biomarker testing that help match the right patient to the right treatment. But do women around the world have equitable access to these breakthroughs? We explore the real-world barriers patients face - from awareness gaps to issues with access and cost - as well as the significant socioeconomic impact of the disease.Host Hannah Vaughan Jones is joined by Isabelle Raq-Coquard, Oncologist, Centre Léon Bérard, Professor of Medecine, Université Claude Bernard Lyon 1 and Co-Chair of the Lancet Commission on Ovarian Cancer. Frances Reid, who led the World Ovarian Cancer Coalition’s groundbreaking Every Woman studies returns to the podcast with her insights.The conversation also looks ahead to more personalised care, the growing focus on prevention (including opportunistic salpingectomy - we explain what this is!), and the real hope that earlier detection and improved treatments could transform outcomes for patients in the years ahead.Listen to the full episode to understand what’s changing - and what still needs to.This episode is sponsored by AbbVie and Verastem.